Technology
A new epicardial pacing lead has been cleared by the U.S. Food and Drug Adminitysration (FDA) as an option for the implant of a pacemaker, defibrillator, or cardiac resynchronization therapy (CRT) device. The lead is indicated when other types of leads cannot be implanted. Examples include patients who have small veins, congenital heart disease, abnormalities of the tricuspid valve or when other leads are already in place, preventing additional leads in the veins.
May 19, 2015
News
Shimadzu Medical Systems USA announced the first U.S. West Coast installation of its Trinias C-12 high performance “crossover” system at Kalispell Regional Medical Center in Kalispell, Montana. Shimadzu dealer/partner Core Medical Imaging Inc. of Kenmore, Washington, completed the installation of the angiographic system, which went into operation at the medical center in late April.
May 19, 2015
Feature
Edwards Lifesciences announced it has temporarily halted its clinical trial of the Fortis mitral transcatheter heart valve. The company said that in consultation with trial investigators, it was decided to voluntarily implement a temporary pause on enrollment in its Fortis clinical program because of evidence of valve thrombosis. The company said the issue warrants additional investigation before restarting enrollment.
May 19, 2015Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
News
Abbott announced that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1. Absorb GT1 combines a fully dissolving stent with a next-generation delivery catheter to help doctors treat people with heart disease. Built upon three generations of delivery catheter innovations, Absorb GT1 refers to the GlideTrack catheter, Abbott’s advanced stent delivery system, which is designed to make it easier for doctors to access and treat diseased vessels in people with coronary artery disease (CAD). The GlideTrack catheter incorporates several design and technology changes that have the potential to improve deliverability and performance.
May 19, 2015
Technology
Medtronic plc announced the Arctic Front Advance ST Cryoablation Catheter has received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation. In Europe, where the Cryoballoon has a broader indication, Arctic Front Advance ST Cryoballoon has received CE Mark for the treatment of patients with atrial fibrillation.
May 18, 2015
News | Patient Engagement
A new service called MyChoiceMD is preparing to launch in Colorado that aims to revolutionize the way patients find, pay for, schedule and track their routine medical care. The service has been incubating in Northern Colorado and has completed a 10-month pilot in Cheyenne under the name Galen. It is targeted at the large population of self-pay patients that includes both insured and uninsured patients.
May 18, 2015Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
A risk assessment algorithm combining clinical risk factors and platelet function test results may help interventional cardiologists better identify patients who stand to benefit from intensive antiplatelet medication after percutaneous coronary intervention (PCI). This assessment is according to results of the TRIAGE study, presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.
May 18, 2015
News
New research reports significant differences between men and women with atrial fibrillation (AF) and the safety of intense physical activity. The study found that both moderate and vigorous levels of exercise are safe for women living with AF. However, vigorous levels of exercise are associated with an increased risk of AF in men. The research, analyzing data from a large-scale or robust patient population of nearly 380,000 patients, was presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.
May 18, 2015
News
Patients with a high-risk paclitaxel drug-eluting stent given the shorter-acting antiplatelet drug cilostazol prior to a surgical procedure safely transitioned off of dual antiplatelet therapy (DAPT) to reduce bleeding risk during their operation. These new findings from the OUTSIDE START study were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.
May 18, 2015Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News
A largest-of-its kind study has found that women who experience menopause at a younger age are at a decreased risk of atrial fibrillation (AF). The study followed nearly 18,000 women and revealed that women experiencing menopause younger than 44 years had a significantly lower risk of AF than women entering menopause between the ages of 44-50. The research was presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.
May 15, 2015
Feature
A new, large-scale study has found adding an electrocardiogram (ECG) to the latest generation of body-worn sensors accurately detects atrial fibrillation (AF) and significantly increases awareness of heart rate and behavior. Body-worn or wearable wireless sensors are increasingly being used to help collect health-related information that can be shared with a doctor through a smartphone application. The study results show that by using ECG sensors with a smartphone application, the general adult population can efficiently track their heart rate data. The new findings were presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions.
May 15, 2015
Feature | EP Lab
A new expert consensus statement by the Heart Rhythm Society (HRS) recommends remote monitoring (RM) become standard of care for patients with cardiovascular implantable electronic devices (CIEDs). The HRS Expert Consensus Statement on Remote Interrogation and Monitoring for Cardiovascular Electronic Implantable Devices was written by an international group of experts and published online in HeartRhythm Journal, the official journal of HRS. This new approach presents a new paradigm for managing patients with CIEDs and will be presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th Annual Scientific Sessions.
May 15, 2015Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Feature
Prasugrel (Effient) is more likely to be given to lower-risk heart disease patients undergoing percutaneous coronary intervention (PCI) compared to clopidogrel, according to a new study. Results of the PROMETHEUS study, which examined how the two drugs are used across academic medical centers in the United States, were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.
May 15, 2015
Technology
Geneva Healthcare will showcase a set of new features on The Geneva Healthcare Suite – a technology platform for managing data from cardiac devices – at Heart Rhythm Society's annual scientific sessions in Boston. The cloud-based software suite organizes device data from multiple sources on an intuitive dashboard to provide critical health information to clinicians in real time. New features in The Geneva Healthcare Suite 2.0 focus on streamlining practice workflow and patient engagement with automated reminders, notifications and follow-up for remote monitoring that create an open channel of communication between doctor and patient.
May 15, 2015
News
St. Jude Medical Inc. announced CE Mark approval of expanded labeling for its Ellipse implantable cardioverter defibrillator (ICD), in addition to its Durata and Optisure defibrillation leads. The approvals allow existing or future patients with these technologies to undergo magnetic resonance imaging (MRI) scans without compromising device performance. The company also announced that it has received CE Mark approval for its Assurity MRI and Endurity MRI pacemaker device families. The approvals further expand St. Jude Medical’s MRI-conditional device portfolio in Europe.
May 15, 2015© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now